Defining the Future of Chemotherapy in the Treatment of Early-Stage NSCLC

The Center for Biomedical Continuing Education
Last Modified: August 7, 2005

Conference Dates: Aug 1 - Oct 31 2005
Conference Location: N/A Telesession

Sponsoring Group: The CBCEtm (The Center for Biomedical Continuing Education)

Conference Web Page URL:

Topics Covered: Five-year survival for patients with NSCLC is currently only 15%,largely due to the fact that only approximately half of these patients have surgically resectable disease. Furthermore, among those who can be surgically treated,less than half will be cured by surgery. In 2004, two large studies conducted by the National Cancer Institute of Canada and Cancer and Leukemia Group B reported a significant survival advantage among patients with locally advanced NSCLC treated with adjuvant chemotherapy, validating the efficacy of such regimens. A possible factor in the success of both trials may be attributed to use of third-generation chemotherapeutic agents, which appear to be better tolerated. Based on these data, adjuvant chemotherapy is generally now considered the standard of care for the treatment of patients with completely resected early-stage NSCLC. However, some patients with significant comorbidities may be unable to tolerate adjuvant therapy. In these populations, neoadjuvant chemotherapy is being investigated.

Who Should Attend: Oncologists

Conference Agenda: The interactive format of this activity allows participants to discuss their cases with colleagues and a thought leader in the field of non–small cell lung cancer (NSCLC), following a 20-minute presentation by a member of the program faculty.

Registration Information: For complete brochure and registration instructions, please visit our website at

Conference Fees: Complimentary

Continuing Education: Yes

Miscellany: For complete brochure, please see